ArticleInternational journal of cancer2026
5-Aminolevulinic Acid Photodynamic Therapy for Non-Lesional Persistent High-Risk HPV Infection: A Comparative Cohort Study With Interferon.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Possible spatially-distinctFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Persistent high-risk human papillomavirus (HR-HPV) infection drives cervical carcinogenesis, yet effective treatments for patients without histologically confirmed cervical lesions are lacking. Although five-aminolevulinic acid photodynamic therapy (ALA-PDT) effectively treats cervical lesions and associated HR-HPV, its efficacy for clearing HR-HPV in non-lesional patients is unclear. We aim to compare the efficacy of ALA-PDT versus interferon (IFN) in treating persistent HR-HPV infection in patients without cervical lesions. This real-world cohort study included 157 patients receiving three sessions of ALA-PDT and 114 patients receiving 3 courses total of IFN therapy. The primary outcome was HR-HPV complete clearance at 6- and 12-month post-treatment. At 6 months, complete clearance rates were 56.9% (82/144) in the PDT group versus 15.3% (13/85) in the IFN group (p < 0.001). At 12 months, rates were 67.0% (59/88) versus 28.3% (26/92) (p < 0.001). Generalized estimating equations (GEE) analysis confirmed PDT was significantly superior to IFN in reducing persistent infection risk (adjusted odds ratio [aOR] = 0.114, 95% CI: 0.054-0.242, p < 0.001). Longer infection duration (≥ 24 vs. 6-23 months) (aOR = 2.334, 95% CI: 1.352-4.030, p = 0.002) and increasing age (per year) (aOR = 1.025, 95% CI: 1.003-1.048, p = 0.027) were independently associated with higher persistence risk. Adverse events (mild pain and vaginal discharge) occurred in 5.1% of patients. ALA-PDT demonstrates superior and sustained efficacy over IFN for clearing persistent HR-HPV infection in patients without cervical lesions. Older age and longer infection duration are significant risk factors for treatment failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.